Wet AMD can be treated by injecting a drug that inhibits the growth of new blood vessels into the center portion of the eye. The drug blocks a protein called vascular endothelial growth factor, or VEGF, that promotes the growth of new blood vessels.
Two anti-VEGF drugs have been approved by the Food and Drug Administration to treat wet AMD. Both of these drugs, pegaptanib (Macugen) and ranibizumab (Lucentis), are injected into the jellylike central part of the eye and have been shown to slow the progression of the disease. These drugs have also been shown to reverse some of the effects of the disease. As many as 35 percent of patients who receive a monthly injection of ranibizumab, for example, experience improvements in their vision. Although pegaptanib has an advantage of somewhat less frequent dosing, it appears to be less effective for improving vision. The two drugs have not been directly compared.
U.S. News's featured content providers were not involved in the selection of advertisers appearing on this website, and the placement of such advertisement in no way implies that these content providers endorse the products and services advertised. Disclaimer and a note about your health.